Intervention not reported
Improvement in measures of health status at 24 to 60 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health status at 6 to 36 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health behavior at 3 to 48 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health status at 12 to 48 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health behavior at 4 to 36 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health status at 2 to 12 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health behavior at 6 to 36 months of · s
1 finding from 1 review
Intervention not reported
Improvement in measures of health status at 12 to 40 months of · s
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with a clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Postoperative atelectasis original authors’ definitions · adult participants undergoing cardiac and major abdominal surgery
Preoperative inspiratory muscle training may leads to lower postoperative atelectasis original authors’ definitions compared with usual care, non‐exercise intervention (low certainty).
1 finding from 1 review
Postoperative pneumonia original authors’ definitions · adult participants undergoing cardiac and major abdominal surgery
Preoperative inspiratory muscle training probably leads to lower postoperative pneumonia original authors’ definitions compared with usual care, non‐exercise intervention (moderate certainty).
1 finding from 1 review
Mechanical ventilation > 48 hours · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes mechanical ventilation > 48 hours compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes all‐cause mortality within 30 days during postoperative period compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
Adverse events · adult participants undergoing cardiac and major abdominal surgery
1 finding from 1 review
Length of hospital stay · adult participants undergoing cardiac and major abdominal surgery
1 finding from 1 review